NCT02103738: CAN-TREAT

Canadian Treat and Extend Analysis Trial With Ranibizumab

Completed Last updated 5 June 2020

What this trial tests

trial testing 0.5 mg Ranibizumab intravitreal injections in wetAMD in 505 participants. Completed in 31 July 2019.

Timeline

8 May 2013

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	505
Start date	8 May 2013
Primary completion	31 July 2019
Estimated completion	31 July 2019
Sites	24 locations across Canada

Drugs / interventions tested

• 0.5 mg Ranibizumab intravitreal injections

Conditions studied

• wetAMD — all drugs for wetAMD →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 50 to 50, any sex, with wetAMD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study to will evaluate and compare two Ranibizumab treatment regimens (Standard of care) in patients with neovascular (wet) age-related macular degeneration (wAMD) aiming to achieve and to maintain a maximum visual function benefit. The results will be used to generate further recommendations on the timing of treatment administration for patients with neovascular (wet) age-related macular degeneration (wAMD). In this context, the study will use the anatomical imaging (for example, optical coherence tomography \[OCT\]) to evaluate wAMD disease activity impacted by the recurrence of disease instability and for decision making in the treatment decision algorithm.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
   Li E, Donati S, Lindsley KB, Krzystolik MG, et al · · 2020 · cited 87× · PMID 32374423 · DOI 10.1002/14651858.cd012208.pub2
2. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
   Kertes PJ, Galic IJ, Greve M, Williams G, et al · · 2020 · cited 66× · PMID 31917441 · DOI 10.1001/jamaophthalmol.2019.5540
3. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.
   Rosenberg D, Deonarain DM, Gould J, Sothivannan A, et al · · 2023 · cited 54× · PMID 35396574 · DOI 10.1038/s41433-022-02020-7
4. Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society.
   Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, et al · · 2021 · cited 42× · PMID 34839342 · DOI 10.1097/apo.0000000000000445
5. Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison.
   Zhang Y, Gao S, Li X, Huang X, et al · · 2021 · cited 10× · PMID 34992542 · DOI 10.3389/fphar.2021.797108
6. Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.
   Sun H, Li L, Bu F, Xin X, et al · · 2024 · PMID 39261653 · DOI 10.1038/s41433-024-03327-3